WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Info & Links
CEO
Paul B. Bolno
Headquarters
7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE, U0 018936, SINGAPORE
Wave Life Sciences Ltd. Ordinary Shares Statistics
Valuation Measures
Market Capitalization2
1.71B
Enterprise Value
1.40B
Enterprise Value/EBITDA(ttm)
-9.77
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
15.64
Price to Book(mrq)
9.98
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-66.50%
Profit Margin(ttm)
82.72%
Return on Equity(ttm)
-280.57%
Return on Invested Capital(ttm)
737.94%
Return on Assets(ttm)
-52.90%
Income Statement
Revenue(ttm)
53.61M
Revenue Per Share(ttm)
0.35
Gross Profit(ttm)
53.61M
EBITDA(ttm)3
-143.36M
Net Income Available to Common(ttm)
-142.26M
Diluted EPS(ttm)
-1.11
Share Statistics
Beta (5Y Monthly)
-1.09
52-Week Change
171.76%
S&P 500 52-Week Change
18.16%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
152.52M
Dividend Yield
0.00%
Float4
108.14M
% Held by Insiders
29.10%
% Held by Institutions
89.73%
Balance Sheet
Total Cash(mrq)
310.95M
Total Cash Per Share(mrq)
2.04
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
1.90%
Quick Ratio(mrq)
1.90%
Book Value Per Share(mrq)
0.95
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.81
Free Cash Flow(ytd)
-108.23M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.